Field effect of two commercial preparations of botulinum toxin type A: A prospective, double-blind, randomized clinical trial

摘要: Background The dose equivalence of commonly used commercial preparations botulinum toxin type A, Dysport (abotulinumtoxinA [ABO] 500 U, Ipsen Biopharm Limited, Wrexham, United Kingdom) and Botox (onabotulinumtoxinA [ONA] 100 Allergan, Irvine, CA), remains unclear. Objective We sought to evaluate the field effect for ABO ONA at equivalences 2.5:1.0 U 2.0:1.0 in both muscular sweat gland activity. Methods In all, 59 female patients with forehead wrinkles were enrolled. Patients randomized between ONA, group A (2.0:1.0 ABO:ONA) or B (2.5:1.0 administered frontalis muscles. Clinical assessment, Minor test, electromyography evaluations performed baseline, 28 days, 112 days. Results B, anhidrotic showed a greater area larger horizontal diameter than At maximum muscle activity (day 112) receiving demonstrated improvement based on Wrinkle Severity Scale. No differences found rest groups results Scale, electromyography, interindividual variability data Limitations Currently, there are no objective measurements other Conclusion (ABO:ONA), similar effects higher injections days ONA.